Health

GSK Plc reports Q3 2024 results with strong growth in Specialty Medicines offsetting lower Vaccine sales. Core earnings rose by 5%, despite Zantac charges...
AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy...
GSK's new antibiotic gepotidacin earns FDA's Priority Review, marking potential first new uUTI oral treatment in 20 years, with decision due March 2025...
GSK welcomes the Florida State Court's Daubert ruling excluding unreliable expert testimony, seeking dismissal of the Wilson case alleging ranitidine-prostate cancer link...
GSK plc welcome favorable jury verdict in Illinois, ruling out any liability for plaintiff's colorectal cancer linked to ranitidine use...
AstraZeneca plc (LON: AZN) has completed the acquisition of Amolyt Pharma, enhancing its rare disease pipeline and expanding its bone metabolism franchise...
Aptamer Group plc has partnered with AstraZeneca to evaluate Optimer® binders for targeted siRNA delivery to fibrotic liver cells, aiming to innovate gene therapies...
GSK plc and CureVac N.V. restructure their collaboration into a licensing agreement, enhancing mRNA vaccine development for influenza and COVID-19...
GSK's Omjjara (momelotinib) gains approval from Japan's MHLW for treating myelofibrosis, addressing anaemia, symptoms, and splenomegaly in patients...
AstraZeneca's Imfinzi gains FDA approval for endometrial cancer treatment. Results show significant benefits for patients with dMMR disease...
Hikma Pharmaceuticals PLC announces agreement to acquire parts of Xellia Pharmaceuticals' US business, expanding its injectables portfolio and manufacturing capabilities...
GSK seeks appeal of recent Daubert ruling in Zantac litigation in Delaware Superior Court. Scientific consensus disputes claim of increased cancer risk...
GSK secures FDA approval for Arexvy in adults aged 50-59 at increased risk for RSV-LRTD. Clinical development ongoing, expanding vaccine benefits globally...
AstraZeneca completes acquisition of Fusion Pharmaceuticals, enhancing its oncology portfolio with next-gen radioconjugates. Learn more here...
Search

Funds

Financial Services

GSK Plc reports Q3 2024 results with strong growth in Specialty Medicines offsetting lower Vaccine sales. Core earnings rose by 5%, despite Zantac charges...
AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy...
GSK's new antibiotic gepotidacin earns FDA's Priority Review, marking potential first new uUTI oral treatment in 20 years, with decision due March 2025...
GSK welcomes the Florida State Court's Daubert ruling excluding unreliable expert testimony, seeking dismissal of the Wilson case alleging ranitidine-prostate cancer link...
GSK plc welcome favorable jury verdict in Illinois, ruling out any liability for plaintiff's colorectal cancer linked to ranitidine use...
AstraZeneca plc (LON: AZN) has completed the acquisition of Amolyt Pharma, enhancing its rare disease pipeline and expanding its bone metabolism franchise...
Aptamer Group plc has partnered with AstraZeneca to evaluate Optimer® binders for targeted siRNA delivery to fibrotic liver cells, aiming to innovate gene therapies...
GSK plc and CureVac N.V. restructure their collaboration into a licensing agreement, enhancing mRNA vaccine development for influenza and COVID-19...
GSK's Omjjara (momelotinib) gains approval from Japan's MHLW for treating myelofibrosis, addressing anaemia, symptoms, and splenomegaly in patients...
AstraZeneca's Imfinzi gains FDA approval for endometrial cancer treatment. Results show significant benefits for patients with dMMR disease...
Hikma Pharmaceuticals PLC announces agreement to acquire parts of Xellia Pharmaceuticals' US business, expanding its injectables portfolio and manufacturing capabilities...
GSK seeks appeal of recent Daubert ruling in Zantac litigation in Delaware Superior Court. Scientific consensus disputes claim of increased cancer risk...
GSK secures FDA approval for Arexvy in adults aged 50-59 at increased risk for RSV-LRTD. Clinical development ongoing, expanding vaccine benefits globally...
AstraZeneca completes acquisition of Fusion Pharmaceuticals, enhancing its oncology portfolio with next-gen radioconjugates. Learn more here...
Search

Funds

Health

FTSE 100

Funds